Mucosal leishmaniasis. Current scenario and prospects for treatment

Acta Tropica

Volumn 105, Issue 1, 2008, Pages 1-9

  Amato, Valdir Sabbaga ^a   Tuon, Felipe Francisco ^a   Bacha, Hélio Arthur ^a   Neto, Vicente Amato ^a   Nicodemo, Antonio Carlos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

American tegumentary leishmaniasis; Amphotericin B; Leishmania; Leishmania (Viannia) braziliensis; Lipid formulations of amphotericin B; Miltefosine; Mucosal leishmaniasis; Pentamidine; Pentavalent antimonial

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; AZITHROMYCIN; FUNGIZON; ITRACONAZOLE; KETOCONAZOLE; MEFLOQUINE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

DEVELOPING WORLD; DISEASE TREATMENT; DRUG; HEALTH CARE; HEALTH RISK; PUBLIC HEALTH;

AMASTIGOTE; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIPROTOZOAL ACTIVITY; CHAGAS DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; HUMAN; HYPOGLYCEMIA; HYPOTENSION; LEISHMANIA BRAZILIENSIS; LEUKOPENIA; LIVER FAILURE; NAUSEA; NONHUMAN; PANCREATITIS; RELAPSE; REVIEW; SIDE EFFECT; SKIN LEISHMANIASIS; ST SEGMENT; SYNCOPE; T WAVE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA BLOOD LEVEL; VISCERAL LEISHMANIASIS; VOMITING;

AMPHOTERICIN B; ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; DEOXYCHOLIC ACID; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG COMBINATIONS; ENDEMIC DISEASES; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, MUCOCUTANEOUS; PENTAMIDINE; TRAVEL;

LEISHMANIA BRAZILIENSIS;

EID: 37249030565     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2007.08.003     Document Type: Review

References (110)

1. Adler-Moore J., and Proffitt R.T. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. 49 Suppl. 1 (2002) 21-30
2. Akuffo H., Dietz M., Teklemariam S., Tadesse T., Amare G., and Berhan T.Y. The use of itraconazole in the treatment of leishmaniasis caused by Leishmania aethiopica. Trans. R. Soc. Trop. Med. Hyg. 84 (1990) 532-534
3. Al-Abdely H.M., Graybill J.R., Loebenberg D., and Melby P.C. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob. Agents Chemother. 43 (1999) 2910-2914
4. Albanese G., Giorgetti P., Santagostino L., Crippa D., and Sala G. Cutaneous leishmaniasis. Treatment with itraconazole. Arch. Dermatol. 125 (1989) 1540-1542
5. Alrajhi A.A., Saleem M., Ibrahim E.A., and Gramiccia M. Leishmaniasis of the tongue in a renal transplant recipient. Clin. Infect. Dis. 27 (1998) 1332-1333
6. Amato V., Amato J., Nicodemo A., Uip D., mato-Neto V., and Duarte M. Treatment of mucocutaneous leishmaniasis with pentamidine isothionate. Ann. Dermatol. Venereol. 125 (1998) 492-495
7. Amato V.S., Boulos M.I., Amato N.V., and Filomeno L.T. The use of a silicone T tube for the treatment of a case of American mucocutaneous leishmaniasis with tracheomalacia. Rev. Soc. Bras. Med. Trop. 28 (1995) 129-130
8. Amato V.S., Padilha A.R., Nicodemo A.C., Duarte M.I., Valentini M., Uip D.E., Boulos M., and Neto V.A. Use of itraconazole in the treatment of mucocutaneous leishmaniasis: a pilot study. Int. J. Infect. Dis. 4 (2000) 153-157
9. Amato V.S., Rabello A., Rotondo-Silva A., Kono A., Maldonado T.P., Alves I.C., Floeter-Winter L.M., Neto V.A., and Shikanai-Yasuda M.A. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop. 92 (2004) 127-132
10. Amato V.S., Tuon F.F., Campos A., Bacha H.A., Nicodemo A.C., Neto V.A., and Shikanai-Yasuda M.A. Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B. Clin. Infect. Dis. 44 (2007) 311-312
11. Amato V.S., Tuon F.F., Siqueira A.M., Nicodemo A.C., and Amato Neto V. Treatment of Mucosal Leishmaniasis in Latin America: systematic review. Am. J. Trop. Med. Hyg. 77 (2007) 266-274
12. Andersen E.M., Cruz-Saldarriaga M., Llanos-Cuentas A., Luz-Cjuno M., Echevarria J., Miranda-Verastegui C., Colina O., and Berman J.D. Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 72 (2005) 133-137
13. Avila J.L., and Casanova M.A. Comparative effects of 4-aminopyrazolopyrimidine, its 2′-deoxyriboside derivative, and allopurinol on in vitro growth of American Leishmania species. Antimicrob. Agents Chemother. 22 (1982) 380-385
14. Bachrach U., bu-Elheiga L., and Schnur L.F. Leishmania tropica major: effect of paromomycin and pentamidine on polyamine levels in the skin of normal and infected mice. Exp. Parasitol. 55 (1983) 280-288
15. Badaro R., Lobo I., Nakatani M., Muinos A., Netto E.M., Coler R.N., and Reed S.G. Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: a case report. Braz. J. Infect. Dis. 5 (2001) 223-232
16. Barral A., Pedral-Sampaio D., Grimaldi J.G., Momen H., Mahon-Pratt D., Ribeiro de J.A., Almeida R., Badaro R., Barral-Netto M., and Carvalho E.M. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am. J. Trop. Med. Hyg 44 (1991) 536-546
17. Barrett M.P., and Fairlamb A.H. The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes. Parasitol. Today 15 (1999) 136-140
18. Basselin M., Denise H., Coombs G.H., and Barrett M.P. Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob. Agents Chemother. 46 (2002) 3731-3738
19. Berger B.J., Carter N.S., and Fairlamb A.H. Polyamine and pentamidine metabolism in African trypanosomes. Acta. Trop. 54 (1993) 215-224
20. Berman J.D. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10 (1988) 560-586
21. Berman J.D. Primary agent for leishmaniasis. Am. J. Trop. Med. Hyg. 38 (1988) 652
22. Berman J.D., Edwards N., King M., and Grogl M. Biochemistry of Pentostam resistant Leishmania. Am. J. Trop. Med. Hyg. 40 (1989) 159-164
23. Beutler B., and Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. Annu. Rev. Immunol. 7 (1989) 625-655
24. Borelli D. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Rev. Infect. Dis. 9 Suppl. 1 (1987) S57-S63
25. Brown M., Noursadeghi M., Boyle J., and Davidson R.N. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br. J. Dermatol. 153 (2005) 203-205
26. Carter N.S., Berger B.J., and Fairlamb A.H. Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J. Biol. Chem. 270 (1995) 28153-28157
27. Castro R.M. Tratamento da Leishmaniose tegumentar americana pela anfotericina B. A propósito de 70 casos. An. Brasil. Dermat. 47 (1972) 229-233
28. Chaudhry Z., Barrett A.W., Corbett E., French P.D., and Zakrzewska J.M. Oral mucosal leishmaniasis as a presenting feature of HIV infection and its management. J. Oral Pathol. Med. 28 (1999) 43-46
29. Choi C.M., and Lerner E.A. Leishmaniasis: recognition and management with a focus on the immunocompromised patient. Am. J. Clin. Dermatol. 3 (2002) 91-105
30. Convit J., Ulrich M., Polegre M.A., Avila A., Rodriguez N., Mazzedo M.I., and Blanco B. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. Mem. Inst. Oswaldo Cruz 99 (2004) 57-62
31. Convit J., Ulrich M., Zerpa O., Borges R., Aranzazu N., Valera M., Villarroel H., Zapata Z., and Tomedes I. Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990-99. Trans. R. Soc. Trop. Med. Hyg. 97 (2003) 469-472
32. Correia D., Silva C.A., and Matthes A.G. Mefloquine in the treatment of cutaneous leishmaniasis. Rev. Soc. Bras. Med. Trop. 32 (1999) 585
33. Croft S.L., and Brazil R.P. Effect of pentamidine isethionate on the ultrastructure and morphology of Leishmania mexicana amazonensis in vitro. Ann. Trop. Med Parasitol. 76 (1982) 37-43
34. Da-Cruz A.M., de Oliveira M.P., De Luca P.M., Mendonca S.C., and Coutinho S.G. Tumor necrosis factor-alpha in human american tegumentary leishmaniasis. Mem. Inst. Oswaldo Cruz 91 (1996) 225-229
35. de Almeida M.C., Vilhena V., Barral A., and Barral-Netto M. Leishmanial infection: analysis of its first steps. A review. Mem. Inst. Oswaldo. Cruz 98 (2003) 861-870
36. de Paula C.D., Sampaio J.H., Cardoso D.R., and Sampaio R.N. A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20mgSbV/day for 20 days to treat cutaneous leishmaniasis. Rev. Soc. Bras. Med. Trop. 36 (2003) 365-371
37. Demicheli C., Ochoa R., da Silva J.B., Falcao C.A., Rossi-Bergmann B., de Melo A.L., Sinisterra R.D., and Frezard F. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis. Antimicrob. Agents Chemother. 48 (2004) 100-103
38. Deps P.D., Viana M.C., Falqueto A., and Dietze R. Comparative assessment of the efficacy and toxicity of N-methyl-glucamine and BP88 sodium stibogluconate in the treatment of localized cutaneous leishmaniasis. Rev. Soc. Bras. Med. Trop. 33 (2000) 535-543
39. Di G.C., Faraut-Gambarelli F., Imbert A., Minodier P., Gasquet M., and Dumon H. Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. J. Antimicrob. Chemother. 44 (1999) 71-76
40. Dietze R., Araujo R.C., Lima M.L., Lexenat J.A., Marsden O.D., and arreto A.C. Ensaio terapeutico com glucantime em saquis (callithrox jacchus) infectados com uma cepa de Leishmania donovani aparentemente resistente ao tratamento. Rev. Soc. Bras. Med. Trop. 18 (1985) 39-42
41. Durand R., Paul M., Pratlong F., Rivollet D., Dubreuil-Lemaire M.L., Houin R., Astier A., and Deniau M. Leishmania infantum: lack of parasite resistance to amphotericin B in a clinically resistant visceral leishmaniasis. Antimicrob. Agents Chemother. 42 (1998) 2141-2143
42. Ellis D. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49 Suppl. 1 (2002) 7-10
43. Ephros M., Bitnun A., Shaked P., Waldman E., and Zilberstein D. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob. Agents Chemother. 43 (1999) 278-282
44. Franke E.D., Llanos-Cuentas A., Echevarria J., Cruz M.E., Campos P., Tovar A.A., Lucas C.M., and Berman J.D. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am. J. Trop. Med. Hyg. 51 (1994) 77-82
45. Franke E.D., Wignall F.S., Cruz M.E., Rosales E., Tovar A.A., Lucas C.M., Llanos-Cuentas A., and Berman J.D. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann. Intern. Med. 113 (1990) 934-940
46. Galvao L.O., Moreira J.S., Medeiros J.P., Lemos G.J., Cunha N.F., Antonino R.M., Santos Filho B.S., and Magalhaes A.V. Therapeutic trial in experimental tegumentary leishmaniasis caused by Leishmania (Leishmania) amazonensis. A comparative study between mefloquine and aminosidine. Rev. Soc. Bras. Med. Trop. 33 (2000) 377-382
47. Gangneux J.P., Dullin M., Sulahian A., Garin Y.J., and Derouin F. Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum. Antimicrob. Agents Chemother. 43 (1999) 172-174
48. Golenser J., and Domb A. New formulations and derivatives of amphotericin B for treatment of leishmaniasis. Mini. Rev. Med. Chem. 6 (2006) 153-162
49. Gomez L., Andrial M., Hosokawa A., Nonade S., and Hashiguchi Y. Oral treatment of new world cutaneous leishmaniasis with mefloquine and artesunate in Ecuador: a preliminary clinical trial. Jpn. J. Trop. Med. Hyg. 23 (1995) 151-157
50. Grant A., Spraggs P.D., Grant H.R., and Bryceson A.D. Laryngeal leishmaniasis. J. Laryngol. Otol. 108 (1994) 1086-1088
51. Grogl M., Oduola A.M., Cordero L.D., and Kyle D.E. Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure. Exp. Parasitol. 69 (1989) 78-90
52. Grogl M., Thomason T.N., and Franke E.D. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 47 (1992) 117-126
53. He S., and Fox T.D. Mutations affecting a yeast mitochondrial inner membrane protein, pnt1p, block export of a mitochondrially synthesized fusion protein from the matrix. Mol. Cell. Biol. 19 (1999) 6598-6607
54. Hendrickx E.P., Agudelo S.P., Munoz D.L., Puerta J.A., and Velez B.I. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am. J. Trop Med Hyg. 59 (1998) 889-892
55. Hentzer B., and Kobayasi T. The ultrastructural changes of Leishmania tropica after treatment with pentamidine. Ann. Trop. Med. Parasitol. 71 (1977) 157-166
56. Iborra C., Caumes E., Carriere J., Cavelier-Balloy B., Danis M., and Bricaire F. Mucosal leishmaniasis in a heart transplant recipient. Br. J. Dermatol. 138 (1998) 190-192
57. Ishikawa E.A., Silveira F.T., Magalhaes A.L., Guerra junior R.B., Melo M.N., Gomes R., Silveira T.G., and Shaw J.J. Genetic variation in populations of Leishmania species in Brazil. Trans. R. Soc. Trop. Med. Hyg. 96 Suppl. 1 (2002) S111-S121
58. Jha T.K., Sundar S., Thakur C.P., Bachmann P., Karbwang J., Fischer C., Voss A., and Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. 341 (1999) 1795-1800
59. Jones T.C., Johnson Jr. W.D., Barretto A.C., Lago E., Badaro R., Cerf B., Reed S.G., Netto E.M., Tada M.S., and Franca T.F. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J. Infect. Dis. 156 (1987) 73-83
60. Lacaz C.S., Paiva L., Sampaio S.A., Godoy J.T., and Mion D. O tratamento da leishmaniose tegumentar americana com a anfotericina B. Rev. Paul Med. 1959 55 (1959) 86
61. Laguna-Torres V.A., Silva C.A., Correia D., Carvalho E.M., Magalhaes A.V., and Macedo V.O. Mefloquine in the treatment of cutaneous leishmaniasis in an endemic area of Leishmania (Viannia) braziliensis. Rev. Soc. Bras. Med. Trop. 32 (1999) 529-532
62. Larson E.E., and Marsden P.D. The origin of espundia. Trans. R. Soc. Trop. Med. Hyg. 81 (1987) 880
63. Lawn S.D., Whetham J., Chiodini P.L., Kanagalingam J., Watson J., Behrens R.H., and Lockwood D.N. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM 97 (2004) 781-788
64. Lessa H.A., Machado P., Lima F., Cruz A.A., Bacellar O., Guerreiro J., and Carvalho E.M. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am. J. Trop. Med. Hyg. 65 (2001) 87-89
65. Llanos-Cuentas A., Echevarria J., Cruz M., La R.A., Campos P., Campos M., Franke E., Berman J., Modabber F., and Marr J. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin. Infect. Dis. 25 (1997) 677-684
66. Machado P.R., Lessa H., Lessa M., Guimaraes L.H., Bang H., Ho J.L., and Carvalho E.M. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin. Infect. Dis. 44 (2007) 788-793
67. Manson-Bahr P.E. East African kalazar with special reference to the pathology, prophylaxis and treatment. Trans. R. Soc. Trop. Med. Hyg. 53 (1959) 123-136
68. Markle W.H., and Makhoul K. Cutaneous leishmaniasis: recognition and treatment. Am. Fam. Physician 69 (2004) 1455-1460
69. Marsden P.D. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans. R. Soc. Trop. Med. Hyg. 80 (1986) 859-876
70. Marsden P.D., Cuba C.C., and Barreto A.C. Allopurinol treatment in human Leishmania braziliensis braziliensis infections. Trans. R. Soc. Trop. Med. Hyg. 78 (1984) 701
71. Marsden P.D., Sampaio R.N., Carvalho E.M., Veiga J.P., Costa J.L., and Llanos-Cuentas E.A. High continuous antimony therapy in two patients with unresponsive mucosal leishmaniasis. Am. J. Trop. Med. Hyg. 34 (1985) 710-713
72. Martinez S., and Marr J.J. Allopurinol in the treatment of American cutaneous leishmaniasis. N. Engl. J. Med. 326 (1992) 741-744
73. Mebrahtu Y.B., Lawyer P.G., Pamba H., Koech D., Perkins P.V., Roberts C.R., Were J.B., and Hendricks L.D. Biochemical characterization and zymodeme classification of Leishmania isolates from patients, vectors, and reservoir hosts in Kenya. Am. J. Trop. Med. Hyg. 47 (1992) 852-892
74. Motta A.C., Arruda D., Souza C.S., and Foss N.T. Disseminated mucocutaneous leishmaniasis resulting from chronic use of corticosteroid. Int. J. Dermatol. 42 (2003) 703-706
75. Nacher M., Carme B., Sainte M.D., Couppie P., Clyti E., Guibert P., and Pradinaud R. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann. Trop. Med. Parasitol. 95 (2001) 331-336
76. Nassiri-Kashani M., Firooz A., Khamesipour A., Mojtahed F., Nilforoushzadeh M., Hejazi H., Bouzari N., and Dowlati Y. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J. Eur. Acad. Dermatol. Venereol. 19 (2005) 80-83
77. Navin T.R., Arana B.A., Arana F.E., Berman J.D., and Chajon J.F. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J. Infect. Dis. 165 (1992) 528-534
78. Nonata R., Sampaio R., and Marsden P.D. Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome. Trans. R. Soc. Trop. Med. Hyg. 91 (1997) 77
79. Oliveira Neto M.P., Schubach A., Araujo M.L., and Pirmez C. High and low doses of antimony (Sbv) in American cutaneous leishmaniasis. A five years follow-up study of 15 patients. Mem. Inst. Oswaldo. Cruz 91 (1996) 207-209
80. Oliveira-Neto M.P., Mattos M., Pirmez C., Fernandes O., Goncalves-Costa S.C., Souza C.F., and Grimaldi Jr. G. Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime) in Rio de Janeiro, Brazil. Rev. Inst. Med. Trop. Sao Paulo 42 (2000) 321-325
81. Oliveira-Neto M.P., Schubach A., Mattos M., Goncalves-Costa S.C., and Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am. J. Trop. Med. Hyg. 57 (1997) 651-655
82. Oliveira-Neto M.P., Schubach A., Mattos M., Goncalves-Costa S.C., and Pirmez C. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathol. Biol. (Paris) 45 (1997) 496-499
83. Osorio L.E., Castillo C.M., and Ochoa M.T. Mucosal leishmaniasis due to Leishmania (Viannia) panamensis in Colombia: clinical characteristics. Am. J. Trop. Med. Hyg. 59 (1998) 49-52
84. Pialoux G., Hennequin C., Dupont B., and Ravisse P. Cutaneous leishmaniasis in an AIDS patient: cure with itraconazole. J. Infect. Dis. 162 (1990) 1221-1222
85. Pourshafie M., Morand S., Virion A., Rakotomanga M., Dupuy C., and Loiseau P.M. Cloning of S-adenosyl-L-methionine:C-24-Delta-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-resistant promastigotes. Antimicrob. Agents Chemother. 48 (2004) 2409-2414
86. Rey J.A., Travi B.L., Valencia A.Z., and Saravia N.G. Infectivity of the subspecies of the Leishmania braziliensis complex in vivo and in vitro. Am. J. Trop. Med. Hyg. 43 (1990) 623-631
87. Rodriguez L.V., Dedet J.P., Paredes V., Mendoza C., and Cardenas F. A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis. Mem. Inst. Oswaldo Cruz 90 (1995) 525-528
88. Rodrigues A.M., Hueb M., Santos T.A., and Fontes C.J. Factors associated with treatment failure of cutaneous leishmaniasis with meglumine antimoniate. Rev. Soc. Bras. Med. Trop. 39 (2006) 139-145
89. Rojas R., Valderrama L., Valderrama M., Varona M.X., Ouellette M., and Saravia N.G. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J. Infect. Dis. 193 (2006) 1375-1383
90. Romero G.A., Lessa H.A., Macedo V., de Carvalho E.M., de Magalhaes A.V., Orge M.d.l., de Abreu M.V., and Marsden P.D. Aminosidine in the treatment of mucocutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Rev. Soc. Bras. Med. Trop. 29 (1996) 215-216
91. Romero G.A., Lessa H.A., Macedo V.O., Carvalho E.M., Barral A., Magalhaes A.V., Orge M.G., Abreu M.V., and Marsden P.D. Open therapeutic study with aminosidine sulfate in mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis. Rev. Soc. Bras. Med. Trop. 29 (1996) 557-565
92. Romero G.A., Lessa H.A., Orge M.G., Macedo V.O., and Marsden P.D. Treatment of mucosal leishmaniasis with aminosidine sulfate: results of two year follow-up. Rev. Soc. Bras. Med. Trop. 31 (1998) 511-516
93. Saldanha A.C., Romero G.A., Guerra C., Merchan-Hamann E., and Macedo V.O. Comparative study between sodium stibogluconate BP 88 and meglumine antimoniate in cutaneous leishmaniasis treatment. II. Biochemical and cardiac toxicity. Rev. Soc. Bras. Med. Trop. 33 (2000) 383-388
94. Saldanha A.C., Romero G.A., Merchan-Hamann E., Magalhaes A.V., and Macedo V.O. A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety. Rev. Soc. Bras. Med. Trop. 32 (1999) 383-387
95. Sampaio R.N., Marchan E.M., Vexenat A., Tristao R.J., and Marsden P.D. Combined antimonial allopurinol therapy in mucosal leishmaniasis. Mem. Inst. Oswaldo Cruz 85 (1990) 373-374
96. Sampaio R.N., and Marsden P.D. Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B. Rev. Soc. Bras. Med. Trop. 30 (1997) 125-128
97. Saravia N.G., Weigle K., Segura I., Giannini S.H., Pacheco R., Labrada L.A., and Goncalves A. Recurrent lesions in human Leishmania braziliensis infection-reactivation or reinfection?. Lancet 336 (1990) 398-402
98. Schwartz E., Hatz C., and Blum J. New world cutaneous leishmaniasis in travellers. Lancet Infect. Dis. 6 (2006) 342-349
99. Scope A., Trau H., Anders G., Barzilai A., Confino Y., and Schwartz E. Experience with New World cutaneous leishmaniasis in travelers. J. Am. Acad. Dermatol. 49 (2003) 672-678
100. Silva-Vergara M.L., Silva L.A., Maneira F.R., da Silva A.G., and Prata A. Azithromycin in the treatment of mucosal leishmaniasis. Rev. Inst. Med. Trop. Sao Paulo 46 (2004) 175-177
101. Silveira T.G., Arraes S.M., Bertolini D.A., Teodoro U., Lonardoni M.V., Roberto A.C., Ramos M., Nerilo S.A., Ishikawa E., and Shaw J. The laboratory diagnosis and epidemiology of cutaneous leishmaniasis in Parana State, southern Brazil. Rev. Soc. Bras. Med. Trop. 32 (1999) 413-423
102. Soto J., Arana B.A., Toledo J., Rizzo N., Vega J.C., Diaz A., Luz M., Gutierrez P., Arboleda M., Berman J.D., Junge K., Engel J., and Sindermann H. Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. 38 (2004) 1266-1272
103. Soto J., Valda-Rodriquez L., Toledo J., Vera-Navarro L., Luz M., Monasterios-Torrico H., Vega J., and Berman J. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 71 (2004) 577-581
104. Soto J., Toledo J., Valda L., Balderrama M., Rea I., Parra R., Ardiles J., Soto P., GOmez A., Molleda F., Fuentelsaz C., Anders G., Sindermann H., Engel J., and Berman J. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin. Infect. Dis. 44 (2007) 350-356
105. Titus R.G., Sherry B., and Cerami A. Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J. Exp. Med 170 (1989) 2097-2104
106. Tuon F.F., and Amato V.S. Mucosal leishmaniasis and miltefosine. Clin. Infect. Dis. 44 (2007) 1525-1526
107. Tuon F.F., Amato V.S., Floeter-Winter L.M., Zampieri R.A., Amato N.V., Franca F.O., and Shikanai-Yasuda M.A. Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids-first report. Int. J. Dermatol. 46 (2007) 628-630
108. Van den E.E., Van G.A., Stevens A., Vandeghinste N., Le R.D., Gigase P., De B.K., and Van den E.J. Treatment of cutaneous leishmaniasis with oral itraconazole. Int. J. Dermatol. 33 (1994) 285-286
109. Velez I., Agudelo S., Hendrickx E., Puerta J., Grogl M., Modabber F., and Berman J. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann. Intern. Med. 126 (1997) 232-236
110. 2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ. Biochem. J. 284 Pt 2 (1992) 463-467